Tower Research Capital LLC TRC Acquires 3,538 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Tower Research Capital LLC TRC boosted its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 319.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,646 shares of the medical instruments supplier's stock after purchasing an additional 3,538 shares during the period. Tower Research Capital LLC TRC's holdings in LeMaitre Vascular were worth $428,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Barclays PLC boosted its stake in shares of LeMaitre Vascular by 394.5% in the 3rd quarter. Barclays PLC now owns 36,577 shares of the medical instruments supplier's stock valued at $3,396,000 after purchasing an additional 29,180 shares during the last quarter. Franklin Resources Inc. boosted its position in LeMaitre Vascular by 5.2% during the third quarter. Franklin Resources Inc. now owns 12,646 shares of the medical instruments supplier's stock valued at $1,165,000 after acquiring an additional 627 shares during the last quarter. Harbor Capital Advisors Inc. grew its holdings in LeMaitre Vascular by 2.8% during the 4th quarter. Harbor Capital Advisors Inc. now owns 24,770 shares of the medical instruments supplier's stock worth $2,282,000 after acquiring an additional 677 shares during the period. Hennion & Walsh Asset Management Inc. raised its position in shares of LeMaitre Vascular by 11.7% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 19,942 shares of the medical instruments supplier's stock worth $1,837,000 after acquiring an additional 2,094 shares in the last quarter. Finally, Annex Advisory Services LLC lifted its stake in shares of LeMaitre Vascular by 5.9% in the 4th quarter. Annex Advisory Services LLC now owns 31,677 shares of the medical instruments supplier's stock valued at $2,919,000 after purchasing an additional 1,769 shares during the period. 84.64% of the stock is owned by institutional investors.

LeMaitre Vascular Stock Performance

Shares of LeMaitre Vascular stock traded up $2.16 during trading hours on Tuesday, reaching $82.60. The company's stock had a trading volume of 23,562 shares, compared to its average volume of 163,141. The stock's fifty day simple moving average is $85.13 and its two-hundred day simple moving average is $93.30. The company has a market capitalization of $1.87 billion, a P/E ratio of 45.22, a P/E/G ratio of 2.22 and a beta of 0.86. LeMaitre Vascular, Inc. has a one year low of $71.42 and a one year high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $0.48 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.50 by ($0.02). LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The company had revenue of $59.87 million for the quarter, compared to analyst estimates of $57.61 million. During the same quarter last year, the firm posted $0.44 EPS. LeMaitre Vascular's revenue for the quarter was up 12.0% on a year-over-year basis. As a group, research analysts forecast that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, May 29th. Shareholders of record on Thursday, May 15th will be issued a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a yield of 0.97%. The ex-dividend date is Thursday, May 15th. LeMaitre Vascular's dividend payout ratio is 40.40%.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on LMAT shares. Lake Street Capital raised their target price on LeMaitre Vascular from $105.00 to $110.00 and gave the stock a "buy" rating in a research note on Friday, February 28th. Wells Fargo & Company started coverage on shares of LeMaitre Vascular in a research note on Thursday, February 13th. They issued an "equal weight" rating and a $95.00 price objective for the company. Barrington Research lowered shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Friday, February 28th. Finally, Oppenheimer lowered shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a report on Friday, February 28th. Five equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $98.14.

Insider Transactions at LeMaitre Vascular

In other LeMaitre Vascular news, insider Trent G. Kamke sold 2,009 shares of the company's stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total value of $164,979.08. Following the completion of the sale, the insider now directly owns 5,564 shares of the company's stock, valued at approximately $456,915.68. This represents a 26.53 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 10.79% of the company's stock.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.